Response to once-monthly and daily oral ibandronate in women with postmenopausal osteoporosis: 2-year findings from mobile

被引：0
|
作者：
Stepan, J. J.
Kendler, D.
Sedarati, F.
Burdeska, A.
Hughes, C.
Lorenc, R.
机构：
[1] Univ Prague, Prague, Czech Republic
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
[4] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[5] Childrens Mem Inst, Warsaw, Poland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：429 / 429
页数：1
相关论文
共 50 条
  • [21] Efficacy and tolerability of once-monthly Ibandronate in postmenopausal osteoporosis
    Dasic, Gorana
    Lewiecki, E. Michael
    Miller, Paul D.
    Sunyecz, John
    Emkey, Ron
    OBSTETRICS AND GYNECOLOGY, 2006, 107 (04): : 91S - 92S
  • [22] Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate is similar in postmenopausal osteoporosis:: 1-year results from mobile
    Adami, S
    Tankó, LB
    Nuti, R
    Leigh, C
    Mairon, N
    Sedarati, F
    Reginster, JY
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 364 - 364
  • [23] Once-Monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women with Postmenopausal Osteoporosis
    Lewiecki, E. Michael
    Keaveny, Tony M.
    Kopperdahl, David L.
    Genant, Harry K.
    Engelke, Klaus
    Fuerst, Thomas
    Kivitz, Alan
    Davies, Richard Y.
    Fitzpatrick, Lorraine A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (01): : 171 - 180
  • [24] Upper gastrointestinal safety and tolerability profile of once-monthly oral ibandronate: Mobile 2-year analysis
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S134 - S134
  • [25] Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate: Results of BALTO II
    Hadji, P.
    Benhamou, C. -L.
    Devas, V.
    Masanauskaite, D.
    Barrett-Connor, E.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S69 - S69
  • [26] Better clinical response for once-monthly compared with daily oral ibandronate
    Sunyecz, J
    OBSTETRICS AND GYNECOLOGY, 2005, 105 (04): : 108S - 108S
  • [27] Once-monthly oral ibandronate (150mg) provides superior efficacy versus daily dosing: 2-year results from mobile
    Felsenberg, D.
    Greenwald, M.
    Need, A.
    Elizondo-Alanis, L-J
    Hughes, C.
    Mairon, N.
    Coutant, K.
    Radominski, S.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S211 - S212
  • [28] Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study (vol 65, pg 654, 2006)
    Reginster, J-Y
    Adami, S.
    Lakatos, P.
    Greenwald, M.
    Stepan, J. J.
    Silverman, S. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (02) : 280 - 280
  • [29] Once-monthly and daily oral ibandronate are at least as effective in improving proximal femur BMD in postmenopausal osteoporosis: 12-month data from MOBILE
    Reginster, JY
    Lorenc, R
    Stepan, JJ
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Cooper, C
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 93 - +
  • [30] Women prefer once-monthly oral ibandronate to weekly oral alendronate as postmenopausal osteoporosis treatment: Results of BALTO II
    Barrett-Connor, E.
    Bourgeois, P.
    Devas, V
    Masanauskaite, D.
    Minne, H.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S234 - S235
12345